Brief: Pharnext announces Phase 3 of PXT3003 for treatment of CMT1A

Pharnext SCA

16/03/2017 16:46

March 16 (Reuters) - Pharnext SAS  PHARN.PA : 
    * Announces initiation of phase 3 extension study 
PLEO-CMT-FU PXT3003 For Treatment Of Charcot-Marie-Tooth Disease 
Type 1A 
    * Plans to apply for marketing authorization for PXT3003 in 
Europe and the United States in Q1 of 2019 
    * Application should lead to PXT3003 market approval during 
second half of 2019, as scheduled 
 
Source text for Eikon:  urn:newsml:reuters.com:*:nBw4TQKFta 
Further company coverage:  PHARN.PA  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))